BiotechTube

Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Oct 1, 2012 → Oct 1, 2013

NCT ID
NCT01742663

About Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel

Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel is a phase 1 stage product being developed by Sun Pharmaceutical for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01742663. Target conditions include Actinic Keratosis.

What happened to similar drugs?

7 of 20 similar drugs in Actinic Keratosis were approved

Approved (7) Terminated (1) Active (13)
✅fluorouracil cream 0.5%SanofiApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
✅Tirbanibulin 2.5 mg ointmentAlmirallApproved
✅TirbanibulinAlmirallApproved
✅Ameluz 10% Topical GelBiofronteraApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01742663Phase 1Completed

Competing Products

20 competing products in Actinic Keratosis

See all competitors
ProductCompanyStageHype Score
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
35
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
29
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
29
Investigational Treatment + Active comparatorNovartisPhase 2
35
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
40
FluorouracilSanofiPhase 1/2
32
fluorouracil cream 0.5%SanofiApproved
43
Imiquimod + DiclofenacViatrisApproved
40
Imiquimod 5 % CreamViatrisPhase 2
32
ImiquimodViatrisPre-clinical
23
Aldara (Imiquimod)ViatrisPhase 3
37
Imiquimod + DiclofenacViatrisApproved
40
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
34
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
34
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
29
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
41
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
34
Tirbanibulin 2.5 mg ointmentAlmirallApproved
37